Ketamine Clinics and Luxury Mental Health
Evidence-based core, wildly variable practice
Ketamine for treatment-resistant depression represents a genuine scientific advance—one of few truly novel mechanisms in psychiatric medication in decades. The FDA has approved esketamine (Spravato) under strict Risk Evaluation and Mitigation Strategy protocols. But ketamine clinics offering IV infusions operate largely outside this framework, with widely varying protocols, monitoring, and pricing.
The Evidence Base
Ketamine does work for depression—this is well-established. The drug's rapid onset (often within hours) distinguishes it from traditional antidepressants requiring weeks to take effect. For patients who haven't responded to multiple medications, ketamine can be transformative.
The challenge is translating research protocols into clinical practice. Studies used specific doses, administration routes, and monitoring. Clinics have adapted these protocols variably, and best practices aren't standardized. What qualifies as appropriate patient selection, dosing, frequency, and integration with other treatment varies dramatically.
Why It Matters for Luxury
Ketamine clinics occupy an unusual position: offering a genuinely effective treatment in a largely unregulated manner. The evidence is real, but the specific implementations vary from careful medical practice to wellness spa aesthetics. Luxury mental health has embraced ketamine partly because it works and partly because the private-pay model allows rapid adoption of new treatments. The quality of what patients actually receive varies enormously.
News & Coverage
- Ketamine's Regulatory Reckoning — Ketamine clinics grew from fewer than 100 in 2015 to over 1,500 by 2024; market estimated at $3.4 billion with enforcement actions now defining standards — October 2024
- FDA Workshop on Ketamine Use — FDA convenes workshop on understanding current use of ketamine for emerging therapeutic areas, signaling increased regulatory attention — June 2024
- ASA: Ketamine Should Only Be Provided by Trained Professionals — American Society of Anesthesiologists responds to misleading statements following Matthew Perry's death from acute ketamine effects — February 2025
- SPRAVATO Approved as Standalone Treatment — FDA approves esketamine nasal spray as first standalone treatment for treatment-resistant depression, establishing regulatory pathway — January 2025
Research
-
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression — July 2023
Anand A, Mathew SJ, Sanacora G, et al. New England Journal of Medicine, 388(25), 2315-2325, 2023. DOI: 10.1056/NEJMoa2302399This landmark randomized trial of 403 patients found ketamine was non-inferior to ECT for treatment-resistant depression, with 55% of ketamine patients showing sustained improvement. The study validates ketamine's efficacy while using standardized IV protocols (0.5 mg/kg over 40 minutes)—protocols that vary widely across commercial clinics.
-
Maintenance Ketamine Treatment for Depression: A Systematic Review of Efficacy, Safety, and Tolerability — February 2023
Smith-Apeldoorn SY, Veraart JKE, Spijker J, et al. Lancet Psychiatry, 9(11), 907-921, 2022. DOI: 10.1016/S2215-0366(22)00317-0This systematic review found that maintenance ketamine treatment appears promising for sustaining antidepressant effects, but notes that optimal long-term protocols are not established. The review highlights variability in dosing, frequency, and administration routes—the same variability seen across commercial ketamine clinics.
-
Extended-Release Ketamine Tablets for Treatment-Resistant Depression: A Randomized Placebo-Controlled Phase 2 Trial — June 2024
Loo CK, et al. Nature Medicine, 2024. DOI: 10.1038/s41591-024-03063-xThis phase 2 trial tested oral extended-release ketamine tablets, finding rapid antidepressant effects while potentially improving safety over IV administration. The development of standardized oral formulations could eventually provide an alternative to the highly variable IV infusion protocols currently offered at commercial clinics.